Journal article

Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy? Impact of Temporal and Observer Variability

Mustafa A Altaha, Mark Nolan, Thomas H Marwick, Emily Somerset, Christian Houbois, Eitan Amir, Paul Yip, Kim A Connelly, Maria Michalowska, Marshall S Sussman, Bernd J Wintersperger, Paaladinesh Thavendiranathan



OBJECTIVES: The purpose of this study was to investigate the effect of the temporal and observer variability of cardiac magnetic resonance (CMR)-measured native T1, T2, and extracellular volume fraction (ECV) and serum biomarkers for the detection of cancer-therapeutics-related cardiac dysfunction (CTRCD). BACKGROUND: Biomarkers and serial quantitative CMR tissue characterization may help identify early myocardial changes of CTRCD, but these parameters require both accuracy and reliability. METHODS: A total of 50 participants (age 48.9 ± 12.1 years) underwent 3 CMR studies (1.5-T) and biomarker measurements (high-sensitivity troponin-I and B-type natriuretic peptide) at 3-month intervals: 20..

View full abstract


Awarded by Canadian Institutes of Health Research

Awarded by Canadian Institutes of Health Research New Investigator Award

Funding Acknowledgements

This study was funded by an operating grant from the Canadian Institutes of Health Research (137132 and 142456). Dr. Marwick has received research grant support for the SUCCOUR study from GE Medical Systems. Dr. Amir has provided expert testimony for Genentech/Roche; and has served as a consultant for Sandoz, Apobiologix, Myriad Genetics, Agendia, and AstraZeneca. Dr. Yip has served as a consultant for and received research and travel honorarium from Abbott Diagnostics. Drs. Connelly and Thavendiranathan (147814) are supported by the Canadian Institutes of Health Research New Investigator Award. Drs. Sussman and Wintersperger are inventors of the patient method of T1 mapping with incomplete tissue magnetization recovery (US 10314548B2; not used in this study). Dr. Wintersperger has received research support and speakers honorarium from Siemens Healthineers. University Health Network has a Master Research Agreement with Siemens Healthineers. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Jagat Narula, MD, served as Guest Editor for this paper.University Health Network, University of Toronto, Toronto, Ontario, Canada; eDivision of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto,